We have entered into a settlement and license agreement with Teva Pharmaceuticals, reflecting the strength of our intellectual property portfolio for low-grade upper tract urothelial cancer (LG-UTUC). Learn more: https://t.co/ddqDCw0ZYh
Men are 3x more likely to be diagnosed with bladder cancer than women. This #MensHealthMonth help educate patients on the warning signs, risks, and treatment options with resources on https://t.co/VgH64GPwSv
Supporting the bladder cancer community is a shared effort. At UroGen, we’re proud to sponsor and participate in @BladderCancerUS’s walks nationwide alongside advocates, families, and healthcare professionals.
With deep expertise across business development, portfolio strategy, and commercial operations, Timothy Simon helps shape our direction and long‑term growth, supporting patients with unmet needs. Learn more: https://t.co/hTERFk0bsZ
Members of our team will participate in a virtual fireside chat for the TD Cowen 7th Annual Oncology Innovation Summit on May 26 at 10:30 AM ET. Tune in to hear our latest news and updates: https://t.co/c1wTm1wy5p
$URGN
Managing recurrent LG-IR-NMIBC requires an understanding of specific risk markers. Intermediate risk is associated with a high burden of recurrence that often necessitates repeat procedures and long-term surveillance. Learn more: https://t.co/HELXalJx0O
Join us for a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the Nasdaq today at 10:30-11:00 AM ET to hear our latest news and updates. https://t.co/KYXsZXwy7I
$URGN
We had a great time in D.C. for #AUA26 and are looking forward to continuing our momentum before we meet again at #AUA27! If you missed us on-site, learn more and connect with us at: https://t.co/fhx0TZ1MJj
At #AUA26, our Chief Medical Officer, Mark Schoenberg, shares how UroGen is working to expand treatment options for people living with urothelial cancers and what that progress means for patients and physicians.
We caught up with Dr. Michael Louie, UroGen’s Chief Development Officer on-site in Washington, D.C. to hear what’s energizing him at #AUA26. Watch to learn what Mike is excited about most this week.
Attending #AUA26? Stop by Booth #2943! Our team members are excited to share our latest innovations as we work to discover new possibilities for #urology patients.
We are pleased to share new six-month duration of response data from the Phase 3 UTOPIA study of UGN-103 (mitomycin) for intravesical solution.
Learn more about the UTOPIA trial and our results: https://t.co/MVmukFbAGy
In bladder cancer, staging describes how deeply a tumor has penetrated the bladder wall. Higher stages indicate greater depth of invasion through the bladder layers, with important implications for management and monitoring. #BladderCancerAwareness
Today, we announced the 36-month duration of response from the Phase 3 ENVISION trial for our treatment for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Learn more about the results: https://t.co/N1ti1ZbyfC
Join our President & CEO, Liz Barrett, and CMO, Mark Schoenberg, for an #AUA26 panel discussion on how clinicians are approaching real-world use of our medication for adults with recurrent LG-IR-NMIBC. https://t.co/W6omyautQK
Our President & CEO, Liz Barrett, will be participating in a fireside chat at the Bank of America 2026 Healthcare Conference in Las Vegas on May 13 at 8:15 AM PT. Register for the webcast: https://t.co/svVZ75OoCA
Today, we will report our Q1 2026 financial results. Tune in today at 10:00 AM ET to listen in on our live earnings call. https://t.co/ClOj3J4QyM
$URGN